Skip to main content

Merkel Cell Carcinoma clinical trials at UCSF

2 in progress, 1 open to eligible people

Showing trials for
  • A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies

    open to eligible people ages 18 years and up

    This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, or lung allograft transplantation and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients. Patients will participate up to approximately 3 years including a 28-day screening period, up to approximately 1 year treatment period, and a 2-year follow-up period.

    San Francisco, California and other locations

  • A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).

    San Francisco, California and other locations

Our lead scientists for Merkel Cell Carcinoma research studies include .

Last updated: